GlycoMimetics Inc. (GLYC)

4.71
0.02 0.42
NASDAQ : Health Technology
Prev Close 4.73
Open 4.69
Day Low/High 4.66 / 4.79
52 Wk Low/High 2.64 / 14.69
Volume 13.30K
Avg Volume 923.20K
Exchange NASDAQ
Shares Outstanding 43.19M
Market Cap 192.21M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GlycoMimetics Reports Top-line Results From Pfizer's Phase 3 Clinical Trial Evaluating Rivipansel In Sickle Cell Disease  

GlycoMimetics Reports Top-line Results From Pfizer's Phase 3 Clinical Trial Evaluating Rivipansel In Sickle Cell Disease  

GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc.

GlycoMimetics Reports Second Quarter 2019 Financial Results And Recent Operational Highlights

GlycoMimetics Reports Second Quarter 2019 Financial Results And Recent Operational Highlights

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended June 30, 2019 and highlighted recent business achievements.

GlycoMimetics To Report Second Quarter 2019 Financial Results On August 1, 2019

GlycoMimetics To Report Second Quarter 2019 Financial Results On August 1, 2019

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to report its second-quarter 2019 financial results on Thursday, August 1, 2019, at 8:30 a.

Interesting GLYC Put And Call Options For March 2020

Interesting GLYC Put And Call Options For March 2020

Investors in GlycoMimetics Inc saw new options begin trading this week, for the March 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Relative Strength Alert For GlycoMimetics

Relative Strength Alert For GlycoMimetics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Noteworthy Tuesday Option Activity: GLYC, FSLR, SHAK

Noteworthy Tuesday Option Activity: GLYC, FSLR, SHAK

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in GlycoMimetics Inc , where a total volume of 2,943 contracts has been traded thus far today, a contract volume which is representative of approximately 294,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.8% of GLYC's average daily trading volume over the past month, of 378,325 shares.

Notable Monday Option Activity: GLYC, INVA, ADVM

Notable Monday Option Activity: GLYC, INVA, ADVM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in GlycoMimetics Inc , where a total volume of 8,485 contracts has been traded thus far today, a contract volume which is representative of approximately 848,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 444.5% of GLYC's average daily trading volume over the past month, of 190,875 shares.

GlycoMimetics To Present At Jefferies 2019 Healthcare Conference

GlycoMimetics To Present At Jefferies 2019 Healthcare Conference

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.

GLYC Makes Bullish Cross Above Critical Moving Average

GLYC Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of GlycoMimetics Inc crossed above their 200 day moving average of $12.49, changing hands as high as $12.66 per share. GlycoMimetics Inc shares are currently trading up about 2.9% on the day.

GlycoMimetics, Inc. Announces Enrollment Completed For Phase 3 Clinical Trial Evaluating Rivipansel In Sickle Cell Disease

GlycoMimetics, Inc. Announces Enrollment Completed For Phase 3 Clinical Trial Evaluating Rivipansel In Sickle Cell Disease

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that patient enrollment has been completed in the Phase 3 RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) clinical trial, which is evaluating the efficacy and safety of rivipansel...

GlycoMimetics Reports First Quarter 2019 Results And Recent Operational Highlights

GlycoMimetics Reports First Quarter 2019 Results And Recent Operational Highlights

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2019 and highlighted recent company achievements.

GlycoMimetics Bolsters Executive Team With Appointment Of Dr. Eric Feldman As Vice President, Clinical Development, And Christian Dinneen-Long As Vice President, Corporate Counsel

GlycoMimetics Bolsters Executive Team With Appointment Of Dr. Eric Feldman As Vice President, Clinical Development, And Christian Dinneen-Long As Vice President, Corporate Counsel

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team.

GlycoMimetics To Report First Quarter 2019 Financial Results On May 2, 2019

GlycoMimetics To Report First Quarter 2019 Financial Results On May 2, 2019

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.

GLYC Makes Bullish Cross Above Critical Moving Average

GLYC Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of GlycoMimetics Inc crossed above their 200 day moving average of $12.80, changing hands as high as $13.09 per share. GlycoMimetics Inc shares are currently trading up about 4.3% on the day.

GlycoMimetics Announces Enrollment Of First Patient In NCI-Sponsored Phase 3 Trial Of Uproleselan In AML

GlycoMimetics Announces Enrollment Of First Patient In NCI-Sponsored Phase 3 Trial Of Uproleselan In AML

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement (CRADA) between GlycoMimetics and the National Cancer...

GlycoMimetics Announces Publication Of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial Of GMI-1359

GlycoMimetics Announces Publication Of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial Of GMI-1359

GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth.

GlycoMimetics Announces Plans To Initiate Breast Cancer Trial To Evaluate GMI-1359

GlycoMimetics Announces Plans To Initiate Breast Cancer Trial To Evaluate GMI-1359

GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone.

GlycoMimetics To Present At Upcoming Investor Conferences

GlycoMimetics To Present At Upcoming Investor Conferences

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that senior management will present corporate updates at two upcoming investor conferences in April.

GlycoMimetics Reports Fourth Quarter And Year-End 2018 Results

GlycoMimetics Reports Fourth Quarter And Year-End 2018 Results

GlycoMimetics, Inc. (Nasdaq:GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2018, highlighted recent company achievements and commented on milestone achievements anticipated in 2019.

GlycoMimetics Announces Transition Plan For Board Of Directors

GlycoMimetics Announces Transition Plan For Board Of Directors

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today planned transitions within the company's Board of Directors.

GlycoMimetics To Report Fourth Quarter And Year-End 2018 Financial Results On March 6, 2019

GlycoMimetics To Report Fourth Quarter And Year-End 2018 Financial Results On March 6, 2019

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.

GlycoMimetics Posters At 60th ASH Annual Meeting Highlight Preclinical Data On Two New Proprietary Drug Candidates

GlycoMimetics Posters At 60th ASH Annual Meeting Highlight Preclinical Data On Two New Proprietary Drug Candidates

GlycoMimetics, Inc. (NASDAQ: GLYC) shared at the 60 th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company's highly potent E-selectin antagonist that is bioavailable via...

GlycoMimetics Presents New AML Data With Uproleselan At 60th ASH Annual Meeting

GlycoMimetics Presents New AML Data With Uproleselan At 60th ASH Annual Meeting

GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that new data on uproleselan-treated high risk patients with both relapsed/refractory and newly diagnosed AML were presented at an oral session during the 60th American Society of Hematology (ASH) Annual...

GlycoMimetics To Host 2018 Investor/Analyst Meeting At 60th ASH Annual Meeting On December 3, 2018

GlycoMimetics To Host 2018 Investor/Analyst Meeting At 60th ASH Annual Meeting On December 3, 2018

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.

Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board Of Directors

Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board Of Directors

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it has appointed Scott Jackson, former Chief Executive Officer of Celator Pharmaceuticals, Inc.

GlycoMimetics Enrolls First Patient In Global Phase 3 Clinical Trial Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia

GlycoMimetics Enrolls First Patient In Global Phase 3 Clinical Trial Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in the company's Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML.

GlycoMimetics Reports Third Quarter 2018 Results And Highlights Recent Company Achievements

GlycoMimetics Reports Third Quarter 2018 Results And Highlights Recent Company Achievements

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2018 and highlighted recent company achievements.

GlycoMimetics To Present Analyses From Phase 1/2 AML Trial Of Uproleselan At 60th ASH Meeting

GlycoMimetics To Present Analyses From Phase 1/2 AML Trial Of Uproleselan At 60th ASH Meeting

GlycoMimetics (NASDAQ: GLYC) announced today that six abstracts covering data from the company's research and clinical portfolio have been accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held...